TWiV 970: Clinical update with Dr. Daniel Griffin
b'
In his weekly clinical update Dr. Griffin\\xa0discusses\\xa0modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir\\u2013Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche\\u2019s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post\\u2013COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Modeling the\\xa0adjustment of COVID-19\\xa0response and exit in China (Nature)
- Canine real-time detection\\xa0of SARS-CoV-2 infections in mass screening events (BMJ)
- N95 respirator failure caused by an\\xa0overlying face mask\\xa0(ICHE)
- Airflow in patient rooms\\xa0may contribute to transmission of severe SARS-CoV-2 (CID)
- Clinical validation of a\\xa0T-Cell receptor\\xa0for identification of recent or prior SARS-CoV-2 infection (CID)
- Antibody-dependent\\xa0cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages (Cell)
- VV116 vs. Nirmatrelvir\\u2013Ritonavir for\\xa0oral treatment\\xa0of Covid-19 (NEJM)
- Nirmatrelvir plus Ritonavir\\xa0for early COVID-19 in a U.S. health system (ACP)
- Molnupiravir as early treatment for\\xa0adults with COVID-19\\xa0(The Lancet)
- Higher dose corticosteroids\\xa0in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support (medRxiv)
- FDA approves\\xa0Tocilizumab\\xa0for the treatment of COVID-19 in hospitalized adults (Roche)
- Structural brain changes in\\xa0post-acute COVID-19\\xa0patients with olfactory dysfunction (Annals)
- Paxlovid patient eligbiliity\\xa0screening checklist (FDA)
- Persistent\\xa0post\\u2013COVID-19\\xa0smell loss association (Science)
- Epidemiology\\xa0of long COVID in US adults (CID)
- Persistent symptoms & sequelae after\\xa0SARS-CoV-2 infection\\xa0not requiring hospitalization (OFID)
- Outpatient treatment\\xa0of COVID-19 with metformin, ivermectin, and fluvoxamine & the development of long COVID (medRxiv)
- Contribute to our\\xa0MicrobeTV fundraiser at PWB
- Dr. Griffin\\u2019s treatment guide (pdf)
- Letters read\\xa0on TWiV 970
- Timestamps by\\xa0Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv